$36.8 Million is the total value of Ponoi II Management, LLC's 4 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NGM | NGM Biopharmaceuticals Inc | $16,652,000 | -15.9% | 1,298,908 | 0.0% | 45.25% | +2.9% | |
| RVMD | Revolution Medicines Inc | $13,351,000 | -23.6% | 685,011 | 0.0% | 36.28% | -6.4% | |
| NRIX | Nurix Therapeutics Inc | $4,145,000 | -9.6% | 327,123 | 0.0% | 11.26% | +10.7% | |
| RAPT | RAPT Therapeutics Inc | $2,654,000 | -17.0% | 145,401 | 0.0% | 7.21% | +1.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NGM Biopharmaceuticals Inc | 8 | Q3 2022 | 45.2% |
| Revolution Medicines Inc | 8 | Q3 2022 | 38.8% |
| Nurix Therapeutics Inc | 8 | Q3 2022 | 24.9% |
| RAPT Therapeutics Inc | 8 | Q3 2022 | 9.7% |
| Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 43.1% |
View Ponoi II Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-08 |
| 4 | 2023-11-17 |
| 4 | 2023-02-01 |
| 4 | 2023-01-25 |
| 4 | 2023-01-23 |
| 4 | 2023-01-17 |
| 4 | 2023-01-12 |
| 4 | 2022-12-14 |
| 4 | 2022-11-23 |
| 13F-HR | 2022-11-14 |
View Ponoi II Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.